The cell lines we have identified as SMARCA4-UT have higher expression of immune and MHC antigen presentation genes than classical neuroendocrine SCLC-A and SCLC-N, raising the possibility that these tumors may respond to immunotherapy. The gene discussed is SMARCA4; the disease is small cell lung carcinoma.